Recro Pharma (REPH) Lowered to “Hold” at Zacks Investment Research

Recro Pharma (NASDAQ:REPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Saturday.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

Several other analysts have also recently commented on REPH. ValuEngine raised shares of Recro Pharma from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 19th. Oppenheimer set a $18.00 price target on shares of Recro Pharma and gave the company a “buy” rating in a research note on Wednesday, August 8th. Janney Montgomery Scott set a $13.00 price target on shares of Recro Pharma and gave the company a “buy” rating in a research note on Monday, October 1st. Finally, Piper Jaffray Companies set a $10.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Recro Pharma currently has a consensus rating of “Buy” and an average price target of $12.88.

REPH opened at $7.35 on Friday. Recro Pharma has a one year low of $4.78 and a one year high of $13.05. The company has a current ratio of 1.59, a quick ratio of 1.42 and a debt-to-equity ratio of 2.22. The company has a market cap of $151.04 million, a PE ratio of -3.69 and a beta of -0.51.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.03. Recro Pharma had a negative net margin of 79.42% and a negative return on equity of 194.05%. The business had revenue of $18.28 million for the quarter, compared to analysts’ expectations of $16.77 million. As a group, equities analysts anticipate that Recro Pharma will post -2.51 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its stake in Recro Pharma by 27.6% in the second quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock valued at $5,747,000 after acquiring an additional 247,559 shares during the last quarter. Newtyn Management LLC bought a new position in Recro Pharma in the second quarter valued at approximately $4,456,000. Engine Capital Management LP boosted its stake in Recro Pharma by 472.3% in the second quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock valued at $1,964,000 after acquiring an additional 322,937 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Recro Pharma by 5.2% in the second quarter. Renaissance Technologies LLC now owns 381,300 shares of the specialty pharmaceutical company’s stock valued at $1,914,000 after acquiring an additional 18,700 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Recro Pharma by 29.5% in the third quarter. Acadian Asset Management LLC now owns 290,124 shares of the specialty pharmaceutical company’s stock valued at $2,063,000 after acquiring an additional 66,062 shares during the last quarter. 54.79% of the stock is currently owned by hedge funds and other institutional investors.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Read More: How is inflation measured?

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply